The medicinal product has been authorised by the European Commission (EC) via centralised procedure in all EU Member States, based on the European Medicines Agency (EMA) experts' opinion.
Name
Ximluci
Active Substance
ranibizumab
Prescription
Medicinal product subject to medical prescription
Type of prescription
Medicinal product subject to restricted medical prescription
Distribution
Supply through pharmacies (community)
ATC Code
S01LA04
Marketing status
Marketed
Shortage status
No shortage
Summary of product characteristics (SmPC), labelling and package leaflet (PL)
